Home  English Website About STADA Sales companies Belgium

International sales activities

Belgium

In Belgium, sales recorded by STADA increased by 14% to EUR 125.7 million in 2009 (previous year: EUR 110.7 million). In addition to new product launches, the Group benefited here especially from a moderate regulatory stimulation of generics prescriptions introduced at the beginning of 2009.

In 2009, generics continued to make the largest contribution to Group sales in Belgium. Generics sales generated by STADA in the Belgian market thus recorded an increase of 14% to EUR 120.2 million (previous year: EUR 105.7 million) in 2009. Generics thus contributed 96% to local sales in 2009 (previous year: 95%). With a market share of approx. 48.9% (previous year: approx. 47.8%), the Belgian STADA subsidiary continued to be the clear local market leader in the generics market there.¹⁾

Branded products, which STADA is currently establishing in the Belgian market, recorded sales of EUR 5.5 million in the financial year 2009 (previous year: EUR 5.0 million) and had a 4% share (previous year: 5%) in Belgian STADA sales. Operating profitability achieved in Belgium in 2009 was above Group average and thus better than expected at the beginning of the year.

In the first three months of 2010 sales generated by STADA in Belgium increased by 13% to EUR 30.0 million (1-3/2009: EUR 26.6 million).

Generics thus continued to have the largest share of local sales in the Belgian market in the first three months of 2010. Generics sales generated by STADA there in the first quarter of 2010 rose by 11% to EUR 28.5 million (1-3/2009: EUR 25.7 million). Generics thus made up 95% of local sales in the first three months of 2010 (1-3/2009: 96%).

STADA generated sales of EUR 1.5 million with branded products in Belgium in the first three months of 2010 (1-3/2009: EUR 0.9 million). Their share of STADA’s Belgian sales thus amounted to 5% (1-3/2009: 4%).

In view of further product launches in the Generics segment, STADA continues to anticipate another significant increase in sales for financial year 2010 with an operating profitability that will continue to be at about Group average.

1)	STADA estimate based on IMS Health data at ex-factory prices.

www.eurogenerics.be

Note: This website is only accessible to medical and pharmaceutical specialists with a personal password.